![](/-/media/editorial/scrip/2022/05/sc2205_kendall-square_1079943437.jpg?rev=eefa6d534b46495998fa965e56a41d37&w=784&hash=876DE6C9BF7A5263CDAC4E4E6464A42D)
Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
![](/-/media/editorial/pink-sheet/2022/04/ps2204_drug-development_m6mghg.jpg?rev=e41e76607cb14b0dae4089d19e1f6c1f&w=784&hash=AAD3405F4509898BFA97EF1769AB2808)
Korea’s Home-Grown New Drug Approvals Hit Record High In 2021
South Korea had a milestone year in terms of domestic new drug approvals in 2021, with multiple major pharma firms gaining nods for their in-house developed products, including the country’s first COVID-19 therapeutic, from Celltrion.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.